Zhongguancun tops China Biopharma Park competitiveness rankings

Zhongguancun Science Park was named China's most competitive biopharmaceutical hub, according to the "2025 China Biopharmaceutical Industrial Park Competitiveness Report" released at the recent China Biotech Innovation Conference held in Chengdu, Sichuan province. 

Suzhou Industrial Park, Shanghai Zhangjiang Science City, Chengdu Hi-Tech Zone, and Wuhan East Lake Hi-Tech Zone followed in the top five.

The report evaluates 208 parks — including 112 national high-tech zones and 80 national economic development zones — across five major categories: environment, industry development, technology, talent, and collaboration. Zhongguancun is placed first in environment, industry, and technology competitiveness.

Zhongguancun's strength is reflected in a growing number of notable innovation stories. In 2015, InnoCare was founeded in Zhongguancun Life Science Park to develop new treatments for blood cancers and autoimmune diseases. Its BTK inhibitor orelabrutinib has since benefited patients in China and expanded into global markets, making the company a rising name in the global innovative drug sector.

Other breakthroughs from Zhongguancun have continued to emerge. METiS TechBio's MTS-004 became China's first AI-enabled formulation drug candidate to complete Phase III clinical trials, while GenAns Biotech's GA001 injection recently received the FDA fast-track designation.

According to Beijing municipal officials, the city will continue to build a modern biopharmaceutical industry cluster as part of its drive to build its International Science and Technology Innovation Center. Beijing plans to deepen cooperation among universities, research institutes, hospitals, and innovative enterprises; promote shared scientific facilities, pilot-scale platforms, and clinical-trial resources; accelerate the use of AI and other new technologies; and strengthen industrial coordination. 

The city will also advance key parks such as the International Pharmaceutical Innovation Park to upgrade supply chains and support global health innovation.